These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29456021)

  • 21. A novel aspartoacylase (ASPA) gene mutation in Canavan disease.
    Durmaz AA; Akin H; Onay H; Vahabi A; Ozkinay F
    Fetal Pediatr Pathol; 2012 Aug; 31(4):236-9. PubMed ID: 22468686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease.
    Leone P; Janson CG; McPhee SJ; During MJ
    Curr Opin Mol Ther; 1999 Aug; 1(4):487-92. PubMed ID: 11713764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pathogenesis of, and pharmacological treatment for, Canavan disease.
    Wei H; Moffett JR; Amanat M; Fatemi A; Tsukamoto T; Namboodiri AM; Slusher BS
    Drug Discov Today; 2022 Sep; 27(9):2467-2483. PubMed ID: 35636725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Canavan's spongiform leukodystrophy: a clinical anatomy of a genetic metabolic CNS disease.
    Baslow MH
    J Mol Neurosci; 2000 Oct; 15(2):61-9. PubMed ID: 11220786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aspartoacylase-lacZ knockin mice: an engineered model of Canavan disease.
    Mersmann N; Tkachev D; Jelinek R; Röth PT; Möbius W; Ruhwedel T; Rühle S; Weber-Fahr W; Sartorius A; Klugmann M
    PLoS One; 2011; 6(5):e20336. PubMed ID: 21625469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.
    McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P
    Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Redirecting
    Gessler DJ; Li D; Xu H; Su Q; Sanmiguel J; Tuncer S; Moore C; King J; Matalon R; Gao G
    JCI Insight; 2017 Feb; 2(3):e90807. PubMed ID: 28194442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myelin lesion in the aspartoacylase (Aspa) knockout rat, an animal model for Canavan disease.
    Takeda S; Hoshiai R; Tanaka M; Izawa T; Yamate J; Kuramoto T; Kuwamura M
    Exp Anim; 2024 Jul; 73(3):347-356. PubMed ID: 38538326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new mouse model of Canavan leukodystrophy displays hearing impairment due to central nervous system dysmyelination.
    Carpinelli MR; Voss AK; Manning MG; Perera AA; Cooray AA; Kile BT; Burt RA
    Dis Model Mech; 2014 Jun; 7(6):649-57. PubMed ID: 24682784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Canavan disease: studies on the knockout mouse.
    Matalon R; Michals-Matalon K; Surendran S; Tyring SK
    Adv Exp Med Biol; 2006; 576():77-93; discussion 361-3. PubMed ID: 16802706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
    Eke GH; Iscan A; Cece H; Calik M
    Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative computational assessment of the pathogenicity of mutations in the Aspartoacylase enzyme.
    George Priya Doss C; Zayed H
    Metab Brain Dis; 2017 Dec; 32(6):2105-2118. PubMed ID: 28879565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aspartoacylase gene knockout in the mouse: impact on reproduction.
    Surendran S; Szucs S; Tyring SK; Matalon R
    Reprod Toxicol; 2005; 20(2):281-3. PubMed ID: 15907664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of central auditory processing in a mouse model of Canavan disease.
    von Jonquieres G; Froud KE; Klugmann CB; Wong AC; Housley GD; Klugmann M
    PLoS One; 2014; 9(5):e97374. PubMed ID: 24826990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcriptional regulation of N-acetylaspartate metabolism in the 5xFAD model of Alzheimer's disease: evidence for neuron-glia communication during energetic crisis.
    Zaroff S; Leone P; Markov V; Francis JS
    Mol Cell Neurosci; 2015 Mar; 65():143-52. PubMed ID: 25766789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel mutation in an Egyptian patient with infantile Canavan disease.
    Zaki OK; El Abd HS; Mohamed SA; Zayed H
    Metab Brain Dis; 2016 Jun; 31(3):573-7. PubMed ID: 26613958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination.
    Mattan NS; Ghiani CA; Lloyd M; Matalon R; Bok D; Casaccia P; de Vellis J
    Neurobiol Dis; 2010 Nov; 40(2):432-43. PubMed ID: 20637282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Canavan disease: clinical features and recent advances in research.
    Hoshino H; Kubota M
    Pediatr Int; 2014 Aug; 56(4):477-83. PubMed ID: 24977939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Canavan disease: a monogenic trait with complex genomic interaction.
    Surendran S; Michals-Matalon K; Quast MJ; Tyring SK; Wei J; Ezell EL; Matalon R
    Mol Genet Metab; 2003; 80(1-2):74-80. PubMed ID: 14567959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up after gene therapy for canavan disease.
    Leone P; Shera D; McPhee SW; Francis JS; Kolodny EH; Bilaniuk LT; Wang DJ; Assadi M; Goldfarb O; Goldman HW; Freese A; Young D; During MJ; Samulski RJ; Janson CG
    Sci Transl Med; 2012 Dec; 4(165):165ra163. PubMed ID: 23253610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.